Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 studyArvind Dasari, Cathy Eng, Takayuki Yoshino et al.|The Lancet|2023Cited by 319
Efficacy and Safety of Sunitinib in Patients with Well-Differentiated Pancreatic Neuroendocrine TumoursÉric Raymond, Nicola Fazio, Matthew H. Kulke et al.|Neuroendocrinology|2018Cited by 55